 |
Dapsone |
|---|---|
| Trade Name | |
| Orphan Indication | Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100 |
| USA Market Approval | USA |
| USA Designation Date | 1994-11-07 00:00:00 |
| Sponsor | Jacobus Pharmaceutical Company, Inc.;37 Cleveland Lane, P.O. Box 5290;Princeton, New Jersey, 08540 |
